Ousia Pharma is a biotech spin-out from the University of Copenhagen developing novel peptide-drug conjugates for treatment of obesity and metabolic diseases. The company uses a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety. A main objective of Ousia Pharma is to advance the development of the lead weight loss drug candidate (OP-56) within general obesity.
| Website | http://www.ousiapharma.com |
| Employees | 8 (4 on RocketReach) |
| Phone | +1 631-504-6093 |
| Industry | Biotechnology Research |
| Competitors | Pfizer, Merck & Co., Inc., Bristol Myers Squibb, Roche, Novartis, Amgen, Gilead Sciences, Lilly India, Sanofi, AstraZeneca +49 more (view full list) |
Looking for a particular Ousia Pharma employee's phone or email?
Anders Klein is the CEO of Ousia Pharma.
4 people are employed at Ousia Pharma.